Research Corporation Technologies Demonstrates Long Half-Life of the CH2 Domain, a New Antibody-Derived Scaffold  
7/11/2012 9:57:22 AM

TUCSON, Ariz.--(BUSINESS WIRE)--Research Corporation Technologies (RCT) and the Protein Interactions Group of the National Cancer Institute at the National Institutes of Health (NIH) have published the first studies in primates that characterize the long half-life of isolated CH2 domains, a new antibody-derived scaffold. The work was performed under a Cooperative Research and Development Agreement (CRADA) between RCT and the NIH.